indomethacin
potent
nonsteroid
inhibitor
prostaglandin
synthetas
cyclooxygenas
reduc
yield
infecti
vesicular
stomat
viru
cell
ad
cultur
level
lo
either
infect
permiss
cell
line
differ
accord
treatment
period
drug
level
requir
restrict
product
infect
inhibitori
effect
indomethacin
progress
reduc
infect
cell
delay
increas
time
drug
remov
strong
inhibit
viral
replic
also
occur
cell
treat
cyclooxygenas
antagonist
naproxen
phenylbutazon
oxyphenylbutazon
wherea
phenacetin
block
cyclooxygenas
function
inact
enhanc
viral
replic
occur
indomethacintr
cultur
cell
subsequ
expos
substanc
prostaglandin
el
cyclic
amp
insulin
convers
indomethacintr
cell
remain
restrict
vsv
subsequ
expos
metabol
inhibitor
function
dna
actinomycin
mitomycin
c
messeng
rna
synthesi
cuamanitin
protein
synthesi
cycloheximid
concentr
normal
compromis
viral
replic
pretreat
cell
mitomycin
c
markedli
shift
dose
respons
indomethacinmedi
inhibit
vsv
inhibitori
dose
one
lo
lower
find
suggest
preexist
host
factor
essenti
replic
wv
although
render
nonfunct
drug
indomethacin
replenish
unless
synthesi
block
variou
class
metabol
inhibitor
genet
biochem
studi
establish
replic
vesicular
stomat
viru
vsv
permiss
cell
requir
unidentifi
host
factor
host
rang
host
restrict
hr
mutant
vsv
previous
isol
laboratori
shown
involv
impair
virusspecif
rna
synthesi
nonpermiss
cell
requir
multipl
host
factor
base
posit
complement
reaction
certain
combin
mutant
simpson
et
morrongiello
simpson
two
hr
mutant
recent
shown
involv
defect
vitro
methyl
viral
mrna
speci
horikami
moyer
author
request
reprint
address
hostdepend
temperaturesensit
mutant
vsv
defici
transcriptas
function
also
describ
szilagyi
pringl
inabl
virionbound
rna
polymeras
transcrib
complementari
genomelength
rna
vitro
reaction
provid
system
demonstr
essenti
role
host
control
element
biosynthet
function
vsv
fulllength
complement
genom
rna
synthes
vitro
virion
nucleocapsid
supplement
crude
extract
infect
cell
batthumphri
et
coupl
transcriptiontransl
system
contain
intracellular
viral
nucleocapsid
complex
without
ad
vsv
mrna
hill
et
al
davi
wertz
presum
latter
system
also
contain
one
host
factor
associ
influenc
function
viral
replic
complex
depend
vsv
replic
preexist
host
factor
demonstr
present
studi
use
nonsteroid
antiinflammatori
inhibitor
known
compromis
prostaglandin
biosynthesi
cyclic
nucleotid
variou
enzym
system
materi
method
viru
stock
titrat
work
stock
vsvindiana
grown
cell
use
reinforc
rmem
supplement
newborn
calf
serum
nc
viru
stock
store
infect
titrat
viru
stock
yield
infect
cell
line
done
plaqu
assay
monolay
cell
use
establish
method
cell
line
continu
line
helaohio
maintain
rmem
nc
glass
prescript
bottl
plastic
tflask
cultur
need
confluent
monolay
cultur
plastic
dish
use
day
seed
drug
inhibit
experi
plaqu
assay
incub
cultur
carri
humidifi
atmospher
incub
maintain
pretreat
cell
indomethacin
viru
infect
unless
indic
otherwis
pretreat
cell
indomethacin
carri
presenc
rmem
contain
newborn
calf
serum
sinc
higher
serum
level
abolish
reduc
drug
effect
observ
incub
confluent
monolay
cultur
desir
concentr
indomethacin
rmem
hr
longer
cell
wash
balanc
salt
solut
bss
inocul
vsvindiana
input
multipl
pfucel
higher
inocula
adsorb
min
room
temperatur
cultur
wash
bss
infect
cultur
incub
rmem
lack
serum
frozen
incub
hr
mate
ak
chemic
tissu
cultur
media
newborn
calf
serum
cycloheximid
purchas
gibco
laboratori
grand
island
n
indomethacin
phenacetin
phenylbutazon
aspirin
cyclic
adenosin
monophosph
camp
prostaglandin
el
insulin
aamanitin
purchas
sigma
chemic
compani
st
loui
mo
cholera
toxin
actinomycin
mitomycin
c
purchas
calbiothem
san
diego
calif
sodium
butyr
sodium
fluorid
obtain
matheson
cole
bell
norwood
ohio
guanosin
triphosph
gtp
purchas
boehringermannheim
indianapoli
ind
naproxen
purchas
syntex
palo
alto
calif
theophyllin
isoproterenol
gift
dr
otto
j
plescia
oxyphenylbutazon
gift
cibageigi
corpor
summit
n
j
indvm
acin
initi
examin
requir
block
product
infect
variou
cell
line
vsv
use
antagonist
fatti
acid
cyclooxygenas
indomethacin
although
drug
inhibit
prostaglandin
biosynthesi
concentr
lower
glass
et
necessari
pretreat
permiss
cell
indomethacin
order
reduc
yield
vsv
less
yield
untreat
control
cultur
inhibitori
effect
larg
nullifi
cultur
medium
use
either
drug
treatment
postinfect
incub
contain
serum
concentr
higher
inglot
also
found
serum
interfer
viral
inhibitori
effect
variou
antiinflammatori
drug
includ
indomethacin
strong
bind
affin
blood
protein
ferreira
vane
avoid
problem
subsequ
experi
serum
usual
omit
postinfect
medium
use
drug
treatment
low
concentr
eg
block
indomethacin
action
also
import
use
freshli
prepar
solut
indomethacin
sinc
stock
solut
found
lose
potenc
store
rel
brief
period
indomethacin
concentr
use
studi
exhibit
virucid
effect
data
shown
revers
drug
effect
appar
experi
involv
delay
viru
infect
pretreat
cell
indomethacin
remov
drug
thu
progress
rise
amount
infecti
viru
produc
cell
time
drug
remov
viru
infect
increas
tabl
restor
permiss
state
vsv
replic
often
complet
hr
drug
remov
particularli
certain
metabolit
arachadon
cascad
ad
describ
amount
indomethacin
treatment
period
requir
render
cell
highli
restrict
vsv
replic
differ
among
variou
cell
line
test
hela
cell
x
cell
per
petri
plate
pretreat
rmem
contain
freshli
prepar
indomethacin
newborn
calf
serum
nc
hr
infect
treat
cultur
wash
bss
infect
vsv
moi
viru
adsorpt
period
cell
wash
fresh
rmem
lack
sernm
drug
ad
cultur
incub
hr
frozen
viru
yield
measur
plaqu
assay
cell
nd
determin
exampl
drug
concentr
low
produc
signific
inhibit
vsv
helaohio
deriv
line
comparison
cell
less
sensit
drug
level
tabl
differenti
inhibitori
effect
consist
observ
respect
cell
line
test
independ
experi
cell
produc
rel
high
yield
infecti
vsv
particl
found
refractori
action
indomethacin
cell
line
test
properti
illustr
tabl
seen
drug
treatment
period
requir
reduc
subsequ
yield
vsv
cell
greater
differ
drug
sensit
cell
line
examin
could
possibl
reflect
rate
amount
indomethacin
uptak
cell
within
given
time
period
experi
indic
pretreat
variou
permiss
cell
line
indomethacin
concentr
rang
strongli
inhibit
growth
vsv
cell
infect
immedi
drug
treatment
determin
whether
inhibitori
effect
occur
exclus
condit
pretreat
cell
drug
yield
vsv
cell
treat
indomethacin
differ
time
infect
measur
figur
show
viru
yield
strongli
reduc
even
drug
ad
late
hr
viru
infect
find
indic
indomethacin
exhibit
strong
inhibitori
effect
throughout
entir
viral
replic
cycl
rhabdoviru
viral
inhibitori
eflect
variou
nonsteroid
antiinjlammatxnq
drug
sinc
indomethacin
one
seri
nonsteroid
drug
known
abil
compromis
convers
arachadon
acid
cyclic
endoperoxid
mcgiff
natur
interest
test
addit
drug
class
possibl
inhibitori
effect
vsv
permiss
cell
monolay
cultur
cell
treat
hr
six
drug
list
tabl
infect
vsv
without
drug
treatment
indomethacin
potent
drug
test
although
strong
inhibit
viru
yield
obtain
cell
expos
naproxen
phenylbutazon
oxyphenylbutazon
phenacetin
potent
antiinflammatori
drug
lack
cyclooxygenas
inhibitori
activ
neg
activ
experi
tabl
suggest
drug
show
posit
inhibit
viral
growth
may
exert
effect
part
function
molecul
prostaglandin
synthetas
cyclooxygenas
although
target
substanc
exclud
see
discuss
infzuenc
varbu
modul
prostaglandin
cyclic
nucleotid
viru
inhibito
q
e
ect
indomethacin
synthesi
function
prostaglandin
metabolit
arachadon
acid
cascad
select
modifi
variou
drug
hormon
growth
factor
mcgiff
test
varieti
substanc
arachadon
metabolit
determin
whether
could
alter
inhibitori
effect
indomethacin
product
infect
cell
vsv
first
seven
substanc
list
tabl
licat
cell
render
nonpermiss
indomethacin
case
metabolit
pgel
camp
increas
viru
yield
substanc
present
normal
serum
stimulatori
effect
identifi
although
nonspecif
drugbind
effect
serum
protein
exclud
compound
sodium
buyrat
sodium
fluorid
gtp
greatli
intensifi
inhibitori
effect
indomethacin
result
total
block
viral
growth
like
combin
treatment
caus
gener
metabol
debilit
cell
render
nonpermiss
e
ect
metabol
inhibitor
viru
grmth
domettintr
cell
find
certain
prostaglandin
cyclic
nucleotid
modul
effector
molecul
could
enhanc
recoveri
indomethacininhibit
cell
prompt
us
studi
kinet
process
variou
condit
figur
illustr
progress
increas
viru
yield
cell
infect
differ
time
cell
x
ld
cell
omm
plate
pretreat
lo
indomethacin
rmem
nc
hr
infect
vsv
moi
cultur
wash
bss
viru
adsorpt
incub
hr
rmem
contain
substanc
list
concentr
indic
per
millilit
medium
incub
cultur
frozen
viru
content
clarifi
cell
lysat
measur
cultur
standard
plaqu
assay
immedi
drug
treatment
incub
time
interv
indic
fresh
serumfre
medium
contain
either
actinomycin
pgml
camp
f
supplement
postinfect
medium
use
cultur
infect
immedi
indomethacin
treatment
time
contain
supplement
wherea
group
receiv
unsuppl
medium
cultur
incub
hr
infect
viru
content
cell
lysat
obtain
freezingthaw
measur
plaqu
assay
cell
histogram
show
viru
yield
differ
infect
group
follow
post
indomethacin
incub
unsuppl
medium
broken
bar
medium
camp
open
bar
medium
actinomycin
solid
bar
viru
yield
infect
control
cultur
expos
indomethacin
drug
x
pfuml
arrow
remov
indomethacin
acceler
camp
repress
low
concentr
actinomycin
sinc
biosynthesi
vsv
normal
inhibit
even
higher
amount
actinomycin
conclud
drug
effect
observ
direct
cellular
dnadepend
rna
synthesi
need
restor
viral
permiss
state
inhibitor
function
dna
mitomycin
c
also
block
revers
indomethacin
effect
data
shown
also
appropri
determin
whether
antagonist
cellular
transcript
protein
synthesi
block
revers
indomethacin
effect
vsv
replic
indomethacintr
cell
expos
differ
time
infect
protein
synthesi
inhibitor
cycloheximid
concentr
use
alon
inhibitori
effect
growth
viru
tabl
show
cycloheximid
strongli
block
revers
indomethacin
inhibit
incub
period
base
viru
yield
control
use
low
concentr
cycloheximid
obtain
differenti
effect
suggest
earlier
observ
cho
rhim
low
drug
level
revers
phenotyp
virustransform
cell
without
impair
either
cell
growth
total
protein
synthesi
also
found
aamanitin
potent
inhibitor
rna
polymeras
ii
partial
block
recoveri
cell
indomethacin
inhibit
tabl
concentr
use
cuamanitin
inhibit
activ
rna
polymeras
ii
synthesi
eukaryot
mrna
speci
impair
replic
vsv
evan
simpson
eflect
mitomycin
c
dose
respws
indomethucin
consid
possibl
cell
might
show
increas
sensit
indomethacin
much
lower
dose
level
one
treat
host
cell
appropri
metabol
inhibitor
prior
indomethacin
treatment
assum
put
target
molecul
indomethacin
would
undergo
turnov
deplet
condit
accordingli
use
mitomycin
c
sinc
drug
effect
block
dna
function
low
concentr
without
inhibit
growth
vsv
data
shown
sequenti
treatment
cell
first
mitomycin
c
pgml
hr
thereaft
indomethacin
dose
rang
hr
respect
markedli
increas
indomethacin
sensit
viral
replic
fig
dual
treatment
regimen
viral
inhibitori
dose
indomethacin
shift
lo
lower
pronounc
alter
dose
respons
indomethacin
inhibit
vsv
per
monolay
incub
hr
fresh
rmem
nc
contain
lack
indomethacin
pretreat
cultur
wash
bss
infect
vsv
moi
either
immedi
hr
incub
hr
either
regular
rmem
medium
contain
cycloheximid
pgml
cyamanitin
pgml
cultur
infect
hr
treat
drug
postinfect
incub
period
hr
wherea
cultur
group
receiv
unsuppl
serumfre
medium
infect
viru
titer
clarifi
frozenthaw
cultur
lysat
determin
plaqu
assay
cell
missiv
cell
like
reflect
reduct
intracellular
level
endogen
host
factor
essenti
viral
biosynthesi
product
ongo
cellular
metabol
wish
determin
whether
total
length
time
cell
expos
mitomycin
c
correl
dose
indomethacin
requir
inhibit
viral
replic
cell
subject
dual
treatment
drug
concentr
indomethacin
low
lo
normal
inhibit
vsv
cell
see
tabl
reduc
viru
yield
mitomycin
c
ad
either
indomethacin
treatment
start
fig
experi
total
treatment
time
indomethacin
hr
wherea
minimum
maximum
period
cell
expos
mitomycin
c
hr
respect
thu
even
cell
expos
mitomycin
c
last
hr
indomethacin
treatment
period
signific
lower
indomethacin
dose
requir
inhibit
vsv
yield
fig
result
would
suggest
unidentifi
indomethacinsensit
host
factor
cell
essenti
viral
replic
rel
short
live
requir
function
dna
replac
via
normal
transcript
process
find
describ
earlier
cell
resist
cell
inhibitori
effect
indomethacin
viral
replic
wherea
helaohio
cell
rel
drug
sensit
properti
offer
possibl
intracellular
level
turnov
rate
drugsensit
host
factor
requir
vsv
might
respons
differ
observ
determin
minimum
pretreat
period
mitomycin
c
requir
alter
indomethacin
dose
respons
helaohio
cell
respect
figur
illustr
cell
rel
resist
indomethacin
requir
treatment
mitomycin
c
least
hr
order
inhibit
viru
yield
indomethacin
contrast
highli
cultur
result
pretreat
cell
mitomycin
c
subconflu
cultur
contain
approxim
cell
incub
hr
rmem
nc
contain
lack
mitomycin
c
pgml
treatment
individu
cultur
wash
bss
incub
addit
hr
fresh
medium
contain
indomethacin
concentr
rang
infect
cell
vsv
moi
carri
indomethacin
treatment
cultur
incub
hr
unsuppl
serumfre
medium
disrupt
cell
lysat
measur
viru
content
plaqu
titrat
cultur
viru
yield
shown
cell
treat
indomethacin
triangl
mitomycin
indomethacin
describ
circl
mitomycin
c
treatment
alon
appar
effect
viral
replic
yield
control
cultur
x
pfuml
arrow
helaohio
cell
show
dramat
shift
indomethacin
dose
respons
pretreat
mitomycin
c
hr
case
inhibitori
dose
indomethacin
lo
instead
absenc
mitomycin
c
treatment
tabl
fig
result
would
suggest
two
cell
line
differ
either
intrins
level
indomethacinsensit
host
factor
avail
viral
replic
rate
factor
remov
function
pool
studi
shown
treatment
cell
indomethacin
certain
nonsteroid
antiinflammatori
drug
render
nonpermiss
replic
rhabdoviru
vesicular
stomat
viru
conclud
certainti
whether
inhibit
involv
specif
host
factor
gener
metabol
impair
cell
reflect
multipl
target
substrat
inhibit
occur
simpli
level
viru
adsorpt
penetr
indic
abil
indomethacin
block
viral
replic
ad
cell
follow
initi
infect
monolay
cell
expos
mitomycin
c
pgml
rmem
nc
differ
time
either
treatment
indomethacin
lo
lo
initi
total
treatment
period
indomethacin
hr
cell
wash
infect
vsv
pfwcell
incub
hr
drugfre
rmem
lack
serum
viru
infect
cultur
disrupt
freezingthaw
lysat
titrat
infecti
viru
plaqu
assay
cell
abscissa
show
time
addit
mitomycin
c
rel
time
indomethacin
ad
time
cell
period
viru
yield
cell
treat
indo
interest
find
perman
cell
line
test
vari
sensit
drug
reflect
differ
level
indomethacin
requir
suppress
product
infecti
viru
higher
differ
surpris
sinc
recogn
rel
potenc
antiinflammatori
drug
vari
consider
cellfre
enzym
system
prostaglandin
synthetas
cyclooxygenas
deriv
differ
tissu
variou
anim
speci
flower
vane
variou
inhibitori
effect
antagonist
modul
metabolit
prostaglandin
biosynthesi
replic
anim
virus
cell
cultur
system
describ
inglot
report
addit
indomethacin
mm
infect
cell
inhibit
onecycl
growth
four
differ
rna
virus
although
quantit
data
lack
indomethacin
also
shown
block
replic
dna
synthesi
herp
simplex
viru
mous
l
cell
maximum
concentr
similar
use
studi
newton
convers
three
inhibitor
cyclooxygenas
includ
indomethacin
recent
found
block
antivir
effect
interferon
mous
human
cell
challeng
vw
without
exert
strong
viral
inhibitori
effect
maximum
dose
level
mg
per
millilit
sarkar
gupta
metabolit
link
arachadon
acid
cascad
exert
antivir
effect
vitro
includ
prostaglandin
seri
santoro
et
cyclic
nucleotid
camp
robbin
rapp
unifi
concept
emerg
studi
regard
possibl
mode
action
agent
dna
rna
anim
virus
viral
inhibitori
concentr
indomethacin
initi
use
studi
greatli
exceed
amount
necessari
compromis
prostaglandin
biosynthesi
initi
enzym
cyclooxygenas
glass
et
al
protein
kinas
activ
vitro
also
block
high
drug
level
goueli
ahm
wherea
much
lower
concentr
indomethacin
also
inhibitori
sever
enzym
system
includ
phosphodiesteras
flower
vane
presum
owe
affin
antiinflammatori
drug
lipophil
peptid
sequenc
hume
et
although
multipl
target
appar
exist
indomethacin
find
obtain
studi
suggest
inhibit
vsv
drug
involv
one
element
prostaglandin
biosynthet
pathway
first
potent
antagonist
fatti
acid
cyclooxygenas
phenylbutazon
exert
strong
antivir
effect
test
system
wherea
phenacetin
antiinflammatori
drug
activ
cyclooxygenas
inact
suppress
vsv
infect
tabl
second
exogen
addit
pgei
camp
infect
cell
follow
indomethacin
treatment
substanti
reduc
inhibitori
effect
drug
suggest
metabol
block
impos
bypass
manner
recoveri
permiss
state
viral
replic
follow
remov
indomethacin
also
significantli
acceler
physiolog
effect
camp
serum
known
stimul
prostaglandin
biosynthesi
cultur
mammalian
cell
samuelsson
et
al
substanc
theophyllin
isoproterenol
increas
intracellular
camp
level
also
found
counteract
inhibitori
effect
indomethacin
seen
studi
thu
cyclic
nucleotid
may
play
critic
role
drugmedi
inhibit
observ
variou
metabol
inhibitor
cellular
macromolecular
synthesi
shown
modifi
sensit
cultur
cell
inhibit
indomethacin
recoveri
cell
drug
treatment
base
permiss
viral
replic
abil
rel
low
concentr
actinomycin
retard
progress
revers
indomethacin
inhibit
cell
suggest
activ
cellular
transcript
requir
replac
labil
host
factor
compromis
indomethacin
treatment
support
concept
come
find
aamanitin
inhibitor
rna
polymeras
ii
exert
similar
effect
recoveri
indomethacininhibit
cell
sinc
actinomycin
aamanitin
normal
impair
vsv
biosynthesi
effect
obtain
drug
indic
activ
cellular
transcript
import
event
recoveri
cell
indomethacin
inhibit
protein
synthesi
inhibitor
cycloheximid
low
concentr
advers
affect
vsv
replic
also
strongli
interfer
restor
viral
permiss
state
treatment
cell
indomethacin
cycloheximid
actinomycin
may
prevent
revers
indomethacin
effect
directli
interf
prostaglandin
biosynthesi
sinc
pong
et
al
shown
drug
block
releas
membranebound
archadon
substrat
cyclooxygenas
mitomycin
c
use
demonstr
antagonist
function
host
cell
dna
markedli
increas
viral
inhibitori
effect
indomethacin
submicromolar
concentr
fig
indomethacin
lo
concentr
becom
inhibitori
viral
replic
cell
hela
cell
appropri
condit
treatment
mitomycin
c
suggest
indomethacin
may
act
cyclooxygenasedepend
prostaglandin
biosynthesi
rather
enzym
system
known
sensit
indomethacin
rel
higher
drug
concentr
flower
vane
goueli
ahm
observ
cell
requir
prolong
treatment
mitomycin
c
helaohio
cell
affect
signific
shift
indomethacin
dose
respons
could
signifi
indomethacinsensit
host
factor
involv
either
abund
cell
lower
bind
affin
drug
alloster
inhibitor
work
near
complet
indic
indomethacin
sever
affect
vsv
biosynthesi
level
rna
transcript
replic
protein
synthesi
aim
identifi
host
factor
compromis
drug
understand
possibl
role
viral
replic
cycl
prostaglandin
physiolog
effector
influenc
arachadon
acid
cascad
may
ultim
recogn
import
biolog
regulatori
agent
product
infect
vsv
anim
virus
